Pacira BioSciences (PCRX) to Release Earnings on Tuesday

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) is projected to announce its Q2 2025 earnings results before the market opens on Tuesday, July 29th. Analysts expect Pacira BioSciences to post earnings of $0.73 per share and revenue of $183.11 million for the quarter.

Pacira BioSciences Price Performance

Shares of PCRX traded down $0.44 during mid-day trading on Thursday, hitting $21.81. The company's stock had a trading volume of 163,054 shares, compared to its average volume of 799,704. The company has a current ratio of 2.41, a quick ratio of 1.99 and a debt-to-equity ratio of 0.48. The firm has a 50-day simple moving average of $24.42 and a 200 day simple moving average of $24.44. The firm has a market capitalization of $1.01 billion, a P/E ratio of -9.61 and a beta of 0.48. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $27.64.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. Wall Street Zen raised Pacira BioSciences from a "hold" rating to a "buy" rating in a report on Friday, June 6th. HC Wainwright raised their price target on Pacira BioSciences from $48.00 to $65.00 and gave the company a "buy" rating in a report on Tuesday, April 8th. Finally, Needham & Company LLC reduced their price target on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a report on Friday, May 9th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average target price of $26.44.

Insiders Place Their Bets

In related news, SVP Lauren Riker sold 5,578 shares of the firm's stock in a transaction that occurred on Wednesday, June 4th. The stock was sold at an average price of $26.21, for a total value of $146,199.38. Following the completion of the transaction, the senior vice president directly owned 59,564 shares of the company's stock, valued at $1,561,172.44. This trade represents a 8.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Pacira BioSciences

Hedge funds have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Pacira BioSciences by 49.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,104,796 shares of the company's stock valued at $27,454,000 after purchasing an additional 367,869 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Pacira BioSciences by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 27,242 shares of the company's stock valued at $677,000 after purchasing an additional 1,165 shares in the last quarter. Finally, Strs Ohio purchased a new position in Pacira BioSciences during the first quarter worth $75,000. 99.73% of the stock is owned by hedge funds and other institutional investors.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.